Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Campath versus deferred therapy in high-risk early-stage chronic lymphocytic leukemia
2006-006915-61Phase 3Terminated
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoint: Progression-free survival. Started Mar 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-006915-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006915-61.